<div class="row"><div class="col-md-12"><div class="panel panel-success"><div class="panel-heading "><h3 class="panel-title">HTML Table Preview</h3></div>
<table border=1 class="table table-striped table-bordered table-hover table-condensed">
<thead><tr><th title="Field #1">Pathways</th>
<th title="Field #2">Aims</th>
<th title="Field #3">Cell type</th>
<th title="Field #4">Senescence induced</th>
<th title="Field #5">Senescence type</th>
<th title="Field #6">Drugs</th>
<th title="Field #7">Dosage [uM]</th>
<th title="Field #8">Exposure time [h]</th>
<th title="Field #9">Controls</th>
<th title="Field #10">Device</th>
<th title="Field #11">Results</th>
<th title="Field #12">Analysis</th>
<th title="Field #13">Sources</th>
</tr></thead>
<tbody><tr><td>Bcl-2 familly </td>
<td>Test</td>
<td>MEF Ercc1 -/-</td>
<td>5x 20%O2</td>
<td>oxidative stress</td>
<td>Fisetin, Restrevastrol ,luteolin, Rutin, EGLG, Curcumin, Pirfenidone, Acepigenin,  Myricetin, Catechin, Quercetin </td>
<td>5</td>
<td> </td>
<td>Hoechst (all cell) C12FDG (senescent) staining </td>
<td>IN Cell Anlayzer</td>
<td>fisetin get best results as senolytics </td>
<td> </td>
<td>Fisetin is a senotherapeutic that extends health and lifespan </td>
</tr>
<tr><td> </td>
<td>Test</td>
<td>MEF Ercc1 -/-</td>
<td>5x 20%O2</td>
<td>oxidative stress</td>
<td>Fisetin </td>
<td>1 , 6.75 , 7.5 , 15 </td>
<td> </td>
<td>Hoechst (all cell) C12FDG (senescent) staining </td>
<td>IN Cell Anlayzer</td>
<td>Snolytics efficiency coraleted with dosage </td>
<td> </td>
<td> </td>
</tr>
<tr><td> </td>
<td> </td>
<td>IMR90 </td>
<td>24h epoptoside </td>
<td>chemotherapy </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
</tr>
<tr><td>Bcl-XL inhibitors</td>
<td>Test</td>
<td>HUVEC</td>
<td>10Gy radiation </td>
<td> </td>
<td>Fisetin ,A1331852,  A1155463</td>
<td>0-60</td>
<td>72</td>
<td>Caspase 3/7 activity assay + ATPLite kit </td>
<td>Scan plate reader </td>
<td>Effective resultes on HUVEC but not on IMR90</td>
<td>Senescent HUVEC more senssitive to BCL-XL inhibitors </td>
<td>New agents that target senescent cells: the flavone, fisetin, and the BCL-XL inhibitors, A1331852 and A1155463</td>
</tr>
<tr><td> </td>
<td> </td>
<td>IMR90 </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
</tr>
<tr><td> </td>
<td> </td>
<td>Human preadipocyties </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
</tr>
<tr><td> </td>
<td>Test</td>
<td>IMR90 </td>
<td> </td>
<td>DIS /OIS /RS</td>
<td>ABT737</td>
<td>1, 5, 10</td>
<td> </td>
<td>BCL-W, BCL-XL, BCL-2, MCL-1, p16, p53</td>
<td>Western blot </td>
<td>inhibition </td>
<td> </td>
<td>Directed elimination of senescent cells by inhibition of BCL-W and BCL-XL</td>
</tr>
<tr><td> </td>
<td> </td>
<td>MEF </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
</tr>
<tr><td> </td>
<td>Test</td>
<td>WI-38</td>
<td>RAS </td>
<td>IR/OIS/RS</td>
<td>ABT263</td>
<td>0,0.6,1.25, 2.5,5</td>
<td> </td>
<td>PI+ annexinV</td>
<td>flow cytometric apotosis + viability quantification</td>
<td> </td>
<td> </td>
<td>Clearance of senescent cells by ABT263 rejuvenates aged hematopoietic stem cells in mice</td>
</tr>
<tr><td> </td>
<td> </td>
<td>WI-38</td>
<td> </td>
<td>IR</td>
<td>ABT263</td>
<td>0-1</td>
<td> </td>
<td>PI+ annexinV</td>
<td>flow cytometric apotosis + viability quantification</td>
<td> </td>
<td> </td>
<td> </td>
</tr>
<tr><td> </td>
<td> </td>
<td>IMR90 </td>
<td> </td>
<td>IR</td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
</tr>
<tr><td> </td>
<td> </td>
<td>REC</td>
<td> </td>
<td>IR</td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
</tr>
<tr><td> </td>
<td> </td>
<td>MEF</td>
<td> </td>
<td>IR</td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
</tr>
<tr><td>Bcl-2 familly </td>
<td>Test</td>
<td>MEF Ercc1 -/-</td>
<td>5x 20%O2</td>
<td>oxidative stress</td>
<td>Ramacyn, NDGA, Curcumin , Resveratral, Dasatinib+Quercetin, ABT263 </td>
<td> </td>
<td>48</td>
<td>Substrat Xgal + C12FDG </td>
<td>flow cytometry +IN Cell Analyzer 6000 confocal image </td>
<td> </td>
<td> </td>
<td>Identification of HSP90 inhibitors as a novel class of senolytics</td>
</tr>
<tr><td>P13K/AKT </td>
<td>Test</td>
<td>MEF Ercc1 -/-</td>
<td>5x 20%O2</td>
<td>oxidative stress</td>
<td>17-AAG, Geldanamycin </td>
<td>0.03, 0.1, 0.3, 1</td>
<td>48</td>
<td>viability</td>
<td>Cell Tax green assay </td>
<td> </td>
<td> </td>
<td> </td>
</tr>
<tr><td> </td>
<td> </td>
<td>MEF Ercc1 -/-</td>
<td>5x 20%O2</td>
<td>oxidative stress</td>
<td>17-DMAG</td>
<td>0-1</td>
<td>48</td>
<td>viability</td>
<td>Cell Tax green assay </td>
<td> </td>
<td> </td>
<td> </td>
</tr>
<tr><td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td>Flow cytometry </td>
<td> </td>
<td> </td>
<td> </td>
</tr>
<tr><td> </td>
<td>Test</td>
<td>MSC Ercc1 -/-</td>
<td>5x 20%O2</td>
<td>oxidative stress</td>
<td>17-DMAG</td>
<td>0.1</td>
<td>24</td>
<td>annexin V/ 7AAD / C12FDG</td>
<td>Flow cytometry </td>
<td> </td>
<td> </td>
<td> </td>
</tr>
<tr><td> </td>
<td> </td>
<td>IMR90 </td>
<td>etoposide </td>
<td>genotoxicity stress</td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
</tr>
<tr><td> </td>
<td> </td>
<td>WI-38</td>
<td>30 passages</td>
<td>RS</td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
</tr>
<tr><td> </td>
<td>Test</td>
<td>MEF Ercc1 -/-</td>
<td>5x 20%O2</td>
<td>oxidative stress</td>
<td>17-DMAG</td>
<td>0.1</td>
<td> </td>
<td>p21, p16, yH2AX</td>
<td>qRT-PCR</td>
<td>MSC (-60%) SC ; WI38(-30%) </td>
<td> Inhibition of HSP90 lead to destabilisation of AKT and ERK and increased apoptosis</td>
<td> </td>
</tr>
<tr><td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td>Cell diameter and volume </td>
<td>FISH </td>
<td> </td>
<td> </td>
<td> </td>
</tr>
<tr><td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td>p16, IL-6</td>
<td>viewRNA</td>
<td> </td>
<td> </td>
<td> </td>
</tr>
<tr><td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td>HSP90, pAKT, AKT, Actin </td>
<td>Immunoblotting</td>
<td>Inhibition of HSP90, increase in AKT</td>
<td> </td>
<td> </td>
</tr>
<tr><td>P13K/AKT </td>
<td>Test</td>
<td>IMR90 </td>
<td> </td>
<td>IR induced </td>
<td>FOXO4-DRI </td>
<td> </td>
<td>0,8,24,48</td>
<td>p21, pSer15-p53</td>
<td>p21 decreased, p53 increase</td>
<td> </td>
<td> </td>
<td>Targeted apoptosis of senescent cells </td>
</tr>
<tr><td> </td>
<td>Test</td>
<td>IMR90 </td>
<td> </td>
<td>IR induced </td>
<td>FOXO4-DRI </td>
<td>0-100</td>
<td> </td>
<td>Viability , density </td>
<td>xCELLigence</td>
<td> </td>
<td> </td>
<td> </td>
</tr>
<tr><td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td>caspase 3/7 activity assay NucViaiv488</td>
<td>confocal imaging </td>
<td> </td>
<td> </td>
<td> </td>
</tr>
<tr><td> </td>
<td>Test</td>
<td>IMR90 </td>
<td> </td>
<td>IR induced </td>
<td>FOXO4-DRI , ABT737, D+Q </td>
<td>0-20, 0-2, 0-400</td>
<td> </td>
<td>Viability</td>
<td>D+Q inefficient, ABT737 reduce controllled cells viability as well, FOXO4-DRI more selesctive against senescent </td>
<td> </td>
<td> </td>
<td> </td>
</tr>
<tr><td> </td>
<td>Test</td>
<td>IMR90 </td>
<td> </td>
<td>IR induced </td>
<td>FOXO4-DRI </td>
<td> </td>
<td> </td>
<td>Viability </td>
<td>FOXO4-DRI reduced around 60% of IMR90 WI-38 senescent cell  and 50% of BJ senescent cell while less than 10% of control cell change.</td>
<td> </td>
<td> </td>
<td> </td>
</tr>
<tr><td> </td>
<td> </td>
<td>BJ</td>
<td> </td>
<td>IR induced </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
</tr>
<tr><td> </td>
<td> </td>
<td>WI-38</td>
<td> </td>
<td>IR induced </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
</tr>
<tr><td> </td>
<td>Test</td>
<td>IMR90 </td>
<td>doxorubicin induced </td>
<td> </td>
<td>FOXO4-DRI, ABT737</td>
<td>0-20, 0-5</td>
<td> </td>
<td>SAB Gal </td>
<td>DAPI</td>
<td>Viability test, ABT737 reduced viability in control cell as well </td>
<td>FOXO4-DRI proved to be more selective against senescence. </td>
<td> </td>
</tr>
<tr><td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td>p16, FOXO4, IL-1a, IL-6</td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
</tr>
<tr><td>Mitochondria </td>
<td>Test</td>
<td>4T1</td>
<td>doxorubicin 4 days</td>
<td> </td>
<td>MitoTam</td>
<td>0.05, 0.1, 0.5, 1</td>
<td>72</td>
<td>Hoechst (all cell) Annexin V </td>
<td>Flow cytometry </td>
<td> </td>
<td> </td>
<td>Selective elimination of senescent cells by mitochondrial targeting is regulated by ANT2</td>
</tr>
<tr><td> </td>
<td> </td>
<td>MCF7</td>
<td>doxurubicin 8 days</td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td>p16, p21, PAI</td>
<td>qRT-PCR</td>
<td> </td>
<td> </td>
<td> </td>
</tr>
<tr><td> </td>
<td>Test</td>
<td>BJ</td>
<td>100 uM BurdU</td>
<td> </td>
<td>MitoTam</td>
<td>1,2.5,5</td>
<td>48</td>
<td>Hoechst (all cell) Annexin V </td>
<td>Flow cytometry</td>
<td>No damage observed on control cell and high SC apoptosis </td>
<td> </td>
<td> </td>
</tr>
<tr><td> </td>
<td> </td>
<td>BJ</td>
<td> </td>
<td>RS</td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
</tr>
<tr><td> </td>
<td> </td>
<td>RPE-1</td>
<td>100 uM BurdU</td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
</tr>
<tr><td>SA-B-gal</td>
<td>Tracking</td>
<td>SK-MEL-103</td>
<td>pablocidil 7 days</td>
<td>oxidative stress</td>
<td>GalNP(rhodamine) </td>
<td> </td>
<td> </td>
<td>Lysotracker</td>
<td>IVIS spectrum</td>
<td> </td>
<td> </td>
<td>A versatile drug delivery system targeting senescent cells</td>
</tr>
<tr><td> </td>
<td> </td>
<td>NCl-H226</td>
<td>pablocidil 7 days</td>
<td>oxidative stress</td>
<td> </td>
<td> </td>
<td> </td>
<td>SABgal staining kit</td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
</tr>
<tr><td> </td>
<td> </td>
<td>UT-SCC</td>
<td>pablocidil 7 days</td>
<td>oxidative stress</td>
<td> </td>
<td> </td>
<td> </td>
<td>Hoechst</td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
</tr>
<tr><td> </td>
<td>Tracking</td>
<td>NCl-H226</td>
<td>pablocidil 7 days</td>
<td>oxidative stress</td>
<td>GalNP(icg) </td>
<td> </td>
<td> </td>
<td> </td>
<td>IVIS spectrum</td>
<td> </td>
<td> </td>
<td> </td>
</tr>
<tr><td> </td>
<td>Test</td>
<td>SK-MEL-103</td>
<td>pablocidil 14 days</td>
<td> </td>
<td>GalNP(dox)    GalNP(navitoclax) </td>
<td> </td>
<td> </td>
<td>annexin V</td>
<td>confocal microscopy </td>
<td> </td>
<td> </td>
<td> </td>
</tr>
<tr><td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td>FOXM1, p21, ACTB, P-RB1 S887/811</td>
<td>western blot </td>
<td>No therapeutic effect on tumour without palbocicli senescence induced </td>
<td> </td>
<td> </td>
</tr>
<tr><td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td>Myh7, Nppa</td>
<td>western blot </td>
<td> </td>
<td> </td>
<td> </td>
</tr>
<tr><td>SA-G-Gal</td>
<td>Test</td>
<td>IMR90 </td>
<td>RAS with 4OHT 6 days  </td>
<td>OIS</td>
<td>DMG</td>
<td>2.5</td>
<td> </td>
<td>Caspase 3/7 reagent </td>
<td> </td>
<td> </td>
<td> </td>
<td>Galactose-modified duocarmycin prodrugs as senolytics</td>
</tr>
<tr><td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td>0-10</td>
<td> </td>
<td> </td>
<td>Cell survival calculation </td>
<td> </td>
<td> </td>
<td> </td>
</tr>
<tr><td> </td>
<td>Test</td>
<td>IMR90</td>
<td>etoposide</td>
<td> </td>
<td>DMG, ABT263</td>
<td>1,5,10</td>
<td> </td>
<td> </td>
<td>Cell survival calculation </td>
<td>ABT263 better except HMEC</td>
<td> </td>
<td> </td>
</tr>
<tr><td> </td>
<td> </td>
<td>IMR90</td>
<td>doxorubicin </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
</tr>
<tr><td> </td>
<td> </td>
<td>IMR90</td>
<td>Gy</td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
</tr>
<tr><td> </td>
<td> </td>
<td>IMR90</td>
<td> </td>
<td>RS</td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
</tr>
<tr><td> </td>
<td> </td>
<td>HMEC</td>
<td>ER:RAS with 4OHT 6 days</td>
<td> </td>
<td>DMG, ABT263</td>
<td> </td>
<td> </td>
<td> </td>
<td>Cell survival calculation </td>
<td>No effect on ABT263 but DMG inefficient </td>
<td> </td>
<td> </td>
</tr>
<tr><td> </td>
<td>Test</td>
<td>IMR90</td>
<td>ER:RAS with shRNA knockdown B gal</td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
</tr>
<tr><td>CD9 receptors</td>
<td>Tracking</td>
<td>HDF </td>
<td>P8/P20/P23</td>
<td>RS</td>
<td>CD9-Lac/CaCO3(coumarin-6) </td>
<td> </td>
<td> </td>
<td>confocal microscopy</td>
<td>cellular uptake</td>
<td> </td>
<td> </td>
<td>Progressive slowdown/prevention of cellular senescence by CD9 targeted delivery of rapamycin using lactose-wrapped calcium carbonate nanoparticles</td>
</tr>
<tr><td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td>ACS assessements</td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
</tr>
<tr><td> </td>
<td>Test</td>
<td>HDF</td>
<td>P20/P23</td>
<td>RS</td>
<td>CD9-Lac/CaCO3(rapamacyn) </td>
<td> </td>
<td> </td>
<td> H2DCF</td>
<td>FACS</td>
<td> </td>
<td>ROS level diminution</td>
<td> </td>
</tr>
<tr><td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td>p53,p21,CD9 and cyclin D1</td>
<td>western blot </td>
<td> </td>
<td>cell cycle blocking</td>
<td> </td>
</tr>
<tr><td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td>IL-6, IL-8</td>
<td>PCR</td>
<td> </td>
<td> </td>
<td> </td>
</tr>
<tr><td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td>BruD staining </td>
<td>confocal images </td>
<td> </td>
<td> </td>
<td> </td>
</tr>
<tr><td>B2MG</td>
<td>Test</td>
<td>EJp16</td>
<td>tet removal </td>
<td>OIS</td>
<td>B2M nanoMIPS fluorescein tagged </td>
<td> </td>
<td> </td>
<td> </td>
<td>Fluorescent microscopy particules quantification with FACS and ImageJ</td>
<td> </td>
<td> </td>
<td>Detecting and targeting senescent cells using molecularly imprinted nanoparticles</td>
</tr>
<tr><td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td>24h incubation PI </td>
<td>FACS</td>
<td> </td>
<td> </td>
<td> </td>
</tr>
<tr><td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td>cell viability </td>
<td>MTS</td>
<td> </td>
<td> </td>
<td> </td>
</tr>
<tr><td> </td>
<td>Test</td>
<td>EJp16</td>
<td>tet removal </td>
<td>OIS</td>
<td>Oligomycin, gramicidin, ABT263, Quercetin, Dasatinib </td>
<td>0.01, 0.1, 1, 5, 10</td>
<td>48</td>
<td>PI  staining </td>
<td>FACS</td>
<td> </td>
<td> </td>
<td> </td>
</tr>
<tr><td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td>viability </td>
<td>MTS</td>
<td> </td>
<td> </td>
<td> </td>
</tr>
<tr><td> </td>
<td>Test</td>
<td>EJp16</td>
<td>tet removal </td>
<td>OIS</td>
<td>B2M nanoMIPS dasatinib conjugated, dasatinib </td>
<td>10</td>
<td>24</td>
<td>viability </td>
<td>MTS</td>
<td> </td>
<td> </td>
<td> </td>
</tr>
<tr><td>DPP4</td>
<td>Tracking</td>
<td>WI-38</td>
<td>IR</td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td>mRNA </td>
<td>RT-qPCR</td>
<td> </td>
<td> </td>
<td>Identification of senescent cell surface targetable protein DPP4</td>
</tr>
<tr><td> </td>
<td> </td>
<td>HUVEC</td>
<td>4Gy</td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td>DPP4, ACTB</td>
<td>Western blot </td>
<td> </td>
<td> </td>
<td> </td>
</tr>
<tr><td> </td>
<td> </td>
<td>HAEC</td>
<td>4Gy</td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
</tr>
<tr><td> </td>
<td> </td>
<td>WI-38</td>
<td>IR</td>
<td> </td>
<td>Anti-DPP4 antibody targeting DPP4 surface + Nk cells</td>
<td> </td>
<td> </td>
<td>metabolic, viability </td>
<td>MTT</td>
<td> </td>
<td> </td>
<td> </td>
</tr>
<tr><td>Bcl-2 family </td>
<td>Test</td>
<td>BJ</td>
<td>HP treatment </td>
<td> </td>
<td>Quercetin, MNP, MNPQ</td>
<td>2.5, 5, 7.5, 10, 15</td>
<td>24</td>
<td>metabolic, viability </td>
<td>MTT</td>
<td> </td>
<td> </td>
<td>AMPK-mediated senolytic and senostatic activity of quercetin surface functionalized Fe3O4 nanoparticles during oxidant-induced senescence in human fibroblasts</td>
</tr>
<tr><td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td>Cell proliferation </td>
<td>Ki67 staining</td>
<td> </td>
<td> </td>
<td> </td>
</tr>
<tr><td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td>cell counting </td>
<td>TC10</td>
<td> </td>
<td> </td>
<td> </td>
</tr>
<tr><td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td>Muse kit </td>
<td>Cycle cell progresssion </td>
<td> </td>
<td> </td>
<td> </td>
</tr>
<tr><td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td>p21, p53, B actin, GLUT1, LC3B, IFNB, pAMK</td>
<td>western blot </td>
<td> </td>
<td> </td>
<td> </td>
</tr>
<tr><td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td>Cell membrane permeability </td>
<td>dye exclusion assay </td>
<td> </td>
<td> </td>
<td> </td>
</tr>
<tr><td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td>Extracellular acidification rate (ECAR) and Oxygen comsumption rate (OCR)</td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
</tr>
</tbody></table>
</div></div></div>